Bahija Jallal, Ph.D., executive vice president of research and development at MedImmune, has been named to the board of directors of the UM Health Sciences Research Park Corp. Jallal is a member of MedImmune’s executive team and of the research and development leadership team of parent company AstraZeneca.
She oversees research, development, regulatory and clinical activities conducted by a team of more than 2,500 MedImmune employees in Maryland, California and the United Kingdom and has guided R&D through the expansion of its biologics pipeline from 40 drugs to more than 140.
Jallal received a master’s in biology from the Universite de Paris VII in France and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max-Planck Institute of Biochemistry in Martinsried, Germany.